



**Date: April 18, 2024**

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Script Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Certificate under Regulation 40(9) & (10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

---

Pursuant to Regulation 40(9) & (10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith a copy of the certificate issued by Dayal & Maur Company Secretaries, for the financial year ended on March 31, 2024.

Request you to kindly take the above on record.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Pradeep Chugh**  
**Company Secretary and Compliance Officer**

**Encl.:** As above

Dayal & Maur  
Company Secretaries  
2/6 A, LGF, Jungpura-A  
New Delhi-110014  
Tel: +91 11 47534394  
E-mail: dayalmaur@gmail.com

**CERTIFICATE UNDER REGULATION 40(9) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

**FOR THE FINANCIAL YEAR ENDED 31<sup>ST</sup> MARCH, 2024**

We have examined all relevant documents relating to equity shares of Mankind Pharma Limited ("the Company"), CIN: L74899DL1991PLC044843, having its Registered office at 208, Okhla Industrial Estate, Phase-III, New Delhi-110020, maintained & provided electronically by **KFin Technologies Limited**, Registrar and Share Transfer Agent ("RTA") of the Company pertaining to the financial year ended on 31<sup>st</sup> March, 2024\* for the purpose of issuing a Certificate as per Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Based on our examination, explanations & information furnished to us, which to the best of our knowledge and belief were necessary for the purpose of our certification, we hereby certify that:

- A) The Company has not received any request for physical transfer of shares during the financial year ended on 31<sup>st</sup> March, 2024\*.
- B) The company has not received any request relating to sub-division, consolidation, renewal exchange or endorsement of call/allotment monies, reissue of certificates, deletion of name of the deceased holder(s) of the securities, transmission/transposition of securities during the financial year ended on 31<sup>st</sup> March, 2024\*.

Place: New Delhi  
Date: 18.04.2024



For Dayal & Maur  
Company Secretaries

SHAILESH DAYAL  
DAYAL

Digitally signed by  
SHAILESH DAYAL  
Date: 2024.04.18  
13:17:18 +05'30'

Shailesh Dayal  
(Partner)

FCS: 4897, CP No. 7142

FRN: P2007DE092500

UDIN: F004897F000164573

Peer Review Cert. No. 923/2020

\* The equity share capital of the Company was listed on BSE Limited and National Stock Exchange of India Limited with effect from 9<sup>th</sup> May, 2023.

Contact  
Shailesh Dayal: 98112 55855